FRANKFURT (Reuters) - German healthcare group Fresenius said its generic drugs and infusions unit Kabi had ramped up production in China back to normal levels after government-imposed coronavirus quarantine restrictions were eased.
“With a further stabilization of the situation, Fresenius Kabi also expects a gradual resumption of its sales force activities in China,” the company said in a statement on Tuesday.
It added it had not suffered a major interruption of production, allowing it to supply pharmaceuticals and medical devices in China.
Reporting by Ludwig Burger; editing by Scot W. Stevenson
Our Standards: The Thomson Reuters Trust Principles.